AgeX Therapeutics
Alameda · Founded 2017
About AgeX Therapeutics
AgeX is a biotechnology company that develops novel therapeutics for age-related degenerative diseases. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology.
Company Facts
- Founded: 2017
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: Less than $1M
- Total funding: $99.8M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jul 2023)
- Ticker: nyse:AGE
- Website: http://www.agexinc.com/
- Phone: (510)871-4190
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/agex-therapeutics-109588 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.